A STUDY OF PHARMACOKINETICS, WHOLE BODY AND ORGAN DOSIMETRY, AND BIODISTRIBUTION OF FISSION-DERIVED IODINE I 131 TOSITUMOMAB (BEXXAR®) FOR PATIENTS WITH PREVIOUSLY UNTREATED OR RELAPSED FOLLICULAR OR TRANSFORMED NON-HODGKIN'S LYMPHOMA: